Table 1.
Association of TPX2 overexpression with clinicopathological characteristics from gastric cancer patients.
| TPX2 expression, n (%) |
||||
|---|---|---|---|---|
| Variable | Number of patients | + | − | P value |
| Gender | ||||
| Male | 78 | 34 (43.6) | 44 (56.4) | 0.29 |
| Female | 37 | 20 (54.1) | 17 (45.9) | |
| Age (yrs.) | ||||
| < 55 | 59 | 25 (42.4) | 34 (57.6) | 0.31 |
| ≥ 55 | 56 | 29 (51.8) | 27 (48.2) | |
| Tumor size (cm) | ||||
| ≤ 4.0 | 28 | 9 (32.1) | 19 (67.9) | 0.071 |
| > 4.0 | 87 | 45 (51.7) | 42 (48.3) | |
| Tumor location | ||||
| Gastric Cardia | 27 | 17 (63.0) | 10 (37.0) | |
| Body | 36 | 14 (38.9) | 22 (61.1) | |
| Antrum | 48 | 20 (41.7) | 28 (58.3) | |
| Diffuse | 4 | 3 (75.0) | 1 (25.0) | |
| Tumor differentiation | ||||
| Well | 31 | 15 (48.4) | 16 (51.6) | |
| Moderate | 39 | 15 (38.5) | 24 (61.5) | |
| Poor/undifferentiated | 45 | 24 (53.3) | 21 (46.7) | |
| Tumor stages | ||||
| T1+T2+T3+T4a | 84 | 34 (40.5) | 50 (59.5) | 0.022 |
| T4b | 31 | 20 (64.5) | 11 (35.5) | |
| Lymph node metastasis | ||||
| Absent (N0) | 32 | 10 (31.2) | 22 (68.8) | 0.036 |
| Present (N1–3) | 83 | 44 (53.0) | 39 (47.0) | |
| Distant metastasis | ||||
| Absent (M0) | 84 | 31 (36.9) | 53 (63.1) | <0.001 |
| Present (M1) | 31 | 23 (74.2) | 8 (25.8) | |
| AJCC stage | ||||
| I | 30 | 6 (20.0) | 24 (80.0) | |
| II | 13 | 5 (38.5) | 8 (61.5) | |
| III | 42 | 21 (50.0) | 21 (50.0) | |
| IV | 30 | 22 (73.3) | 8 (26.7) | |
TPX2, Targeting protein for Xklp2; AJCC, American Joint Committee on Cancer.
Distant metastases included the peritoneum, liver, transverse colon, pancreas, and bone.